WuXi Biologics: Net profit is expected to grow by 46.3% to 4.908 billion yuan in 2025, with significant growth in both the biopharmaceutical and XDC business segments.

LightningPacketLoss

2026-03-26 16:51:21

Abstract generation in progress

On March 24, WuXi Biologics announced its full-year results for the period ending December 31, 2025. The company’s revenue for 2025 was 21.79 billion yuan, a 16.7% increase year-over-year; gross profit was 10.019 billion yuan, up 30.9%, with the gross profit margin rising to 46.0%; net profit attributable to shareholders was 4.908 billion yuan, a 46.3% increase.

In the management discussion and analysis section, the company mentioned that significant growth was driven by an integrated CRDMO platform and the “Follow and Win with Molecules” strategy, adding 209 integrated projects for a total of 945. Late-stage clinical and commercial manufacturing projects increased to 74 and 25, respectively.

In the notes to the financial statements, cost of sales increased from 11.025 billion yuan to 11.772 billion yuan, a 6.8% rise. Overall, the company achieved notable growth in both its Biologics and XDC segments, with external sales of 15.89 billion yuan for Biologics and 5.9 billion yuan for XDC, demonstrating strong market performance and competitiveness.

(WuXi Biologics Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.